Home | Publications | Diseases place holder
place holder place holder

Diseases

The Cardiovascular Disorders Market Outlook to 2012


Publication Date   February 2008
Publisher   Business Insights
Product Type  
Pages   228
ISBN Number   not applicable
Product Code   RBI169
Ask a question about this product?

Price £1,995.00

approximately: $3,728 | €2,530

Summary


Business Intelligence for the Pharmaceutical Industry

Business Insights' portfolio of healthcare management reports are designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your business forward, and appreciate the importance of accurate, up-to-date, incisive product, market and company analysis. We help you to crystallize your business decisions. The strength of our research and analysis is derived from access to unparalleled databases and libraries of information and the use of proprietary analytic techniques. Business Insights reports are authored by independent experts and contain findings garnered from dedicated primary research. Our authors' leading positions secure them access to interview key executives and to establish which issues will be of greatest strategic significance for the industry. Our healthcare portfolio of reports can be used across a wide range of business functions to assess market conditions and devise future strategy. Our reports cover key areas including strategy, industry analysis, market outlook, new business opportunities and strategic insight

Some key findings from this report...

  • Zetia, Diovan, Crestor and Lipitor were the strongest performing major products of 2006-07. Each of these brands is forecast to maintain patent protection over the short to medium-term.
  • The cardiovascular portfolios of Novartis and AstraZeneca are best positioned for high levels of future growth. Conversely, it is forecast that current market leaders Pfizer,Merck and Sanofi-Aventis will struggle to preserve their market shares over the 2008-12 period.
  • The cardiac therapy area is the only segment forecast to experience a decline in net sales during the forecast period. However, generic competition to Lipitor may also result in the Dyslipidemia market suffering a fall in sales over 2011-12.
  • Thrombosis will be the major growth driver of the cardiovascular area throughout the short-term, whilst heart failure has the most favourable dynamics of any indication for rapid market growth.
  • Heart failure and thrombosis represent the most active areas of current drug development. Increasing competition in these traditionally less competitive therapeutic areas is forecast to become a major trend over the period up to 2012.

The Cardiovascular Market Outlook to 2012

The cardiovascular therapeutic area has historically provided the largest single source of revenue for the pharmaceutical industry. The outlook for the market remains robust, driven by high patient populations and a widespread focus on preventative treatment. However, low growth rates in established indications will prevail due to the growing availability of effective generic medicines and an overall scarcity of innovative new drug launches. Major pharma companies are now primarily focusing efforts upon compliance and protection against the generic threats posed by line extensions and combination treatments. Changes in the competitive positions of leading companies will become inevitable as new revenue sources continue to decline and established portfolios underperform. The Cardiovascular Disorders Market Outlook to 2012 is a new report published by Business Insights that provides comprehensive coverage of every class of drugs across all major cardiovascular indications. Detailed insights into recent key events and future market leaders are also provided, in addition to epidemiological analysis and forecasts for major products over the period 2007-12. With coverage of over 90% of the total market for cardiovascular products, this report profiles the underlying trends and factors driving the market and identifies the most promising areas of potential growth.

Top five reasons to order your copy today

  • Assess patient potential, treatment trends and sales patterns across major cardiovascular indications with this report's analysis of epidemiological studies, unmet medical need, and economic imperatives for stakeholders.
  • Measure the market performance and strategic positioning of major pharmaceutical corporations with this report's evaluation of the franchises and market shares of AstraZeneca, BMS, Daiichi Sankyo, GSK, Merck, Novartis, Pfizer, Sanofi-Aventis and Servier.
  • Discover the market dynamics of the cardiovascular area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting R&D.
  • Compare the future prospects of key players and forecast sales of leading products across major indications to 2012 with this report's analysis of sales focus by drug class, currently marketed portfolios, R&D pipelines, and trends in promotional spend for key brands.
  • Identify the strategies that offer the greatest success potential within the future cardiovascular market and understand the challenges currently facing companies within this therapeutic area.

Key issues examined in this report...

  • Cardiac therapies. Heart failure treatments have become a focal point for cardiovascular drug developments. However, doubts remain over whether the marginal benefits offered by such medicines will be sufficient to generate and sustain high levels of revenue.
  • Combination drugs. Although combination drugs failed to accrue strong sales growth in 2007, the growing acceptance of combination dyslipidemic therapies amongst payors and physicians will favour Merck's Vytorin/Inegy and Novartis' newly launched combination product Exforge (amlodipine/losartan)
  • Empty pipelines. Currently marketed portfolios have taken on greater importance in light of weak late stage pipelines among players such as Merck, BMS and AstraZeneca. This lack of new revenue sources is forecast to depress future growth in the cardiovascular market.
  • Market leaders. Few leading companies are expected to retain their presence in the cardiovascular market, with some major players set to experience drastic declines in revenue over the forecast period.

Your questions answered...

  • Which indications will experience the greatest growth in the global cardiovascular market over the period 2007-12?
  • How will generic competition influence the future of branded products and which defensive strategies provide the most effective protection?
  • How have recent major product launches performed?
  • What is the forecast market size and growth rate over the period 2007-2012 across the major cardiovascular indications?
  • Which pipeline products offer the highest growth potential?
  • What will be the competitive landscape of hypertension, thrombosis, dyslipidemia and arrhythmia in 2012?

Content


  • Executive Summary
    • Patient potential
    • Global market analysis
    • Pipeline analysis
    • Competitive landscape
  • Chapter 1 Epidemiology of Cardiovascular
    • disorders
    • Summary
    • Introduction
    • Cardiovascular Risk Factors
    • Hypertension
    • Overview
    • Diagnosis, treatment and management
    • Epidemiology
    • Forecast epidemiology
    • Dyslipidemia
    • Overview
    • Diagnosis, treatment and management
    • Epidemiology
    • Forecast epidemiology
    • Diabetes
    • Overview
    • Diagnosis, treatment and management
    • Epidemiology
    • Forecast epidemiology
    • Cardiovascular disease
    • Overview
    • Epidemiology
    • Acute thrombotic events
    • Acute coronary syndromes
    • Venous thromboembolism
    • Stroke
    • Cardiovascular procedures
  • Chapter 2 Global market analysis
    • Summary
    • Introduction
    • Market analysis by country
    • Licensing trends
    • Market analysis by drug class
    • Leading brands dynamics
    • Key events in the cardiovascular market
    • Use of ACE inhibitors by pregnant women linked to associated birth defects risks
    • Arrival of generic competition to key brands
    • Positive clinical trials further boost sales generation for major brands Diovan and Lipitor
    • Anti-hypertensives
    • Market analysis by drug class
    • Leading brands in the Anti-hypertensives market
    • ACE Inhibitors (ACEIs)
    • Market dynamics
    • Key brands analysis
    • Beta Blockers
    • Market dynamics
    • Diuretics
    • Market dynamics
    • Key brands analysis
    • Calcium Channel Blockers (CCBs)
    • Market dynamics
    • Key brands analysis
    • Angiotensin Receptor Blockers (ARBs)
    • Market dynamics
    • Key brands analysis
    • Sales forecasts to 2012 for Anti Hypertensives
    • Anti-dyslipidemics
    • Market analysis by drug class
    • Leading brands in the Anti-dyslipidemics market
    • Market analysis by drug class
    • Statins
    • Fibrates
    • Non-statin products
    • Other anti-dyslipidemics
    • Sales forecasts to 2012 for Anti dyslipidemics
    • Anti-Thrombotics
    • Market analysis by drug class
    • Leading brand dynamics
    • Anti-platelets
    • Market dynamics
    • Key brands analysis
    • Heparins
    • Market dynamics
    • Key brands analysis
    • Vit K antagonists
    • Fibrinolytics
    • Sales forecasts to 2012 for Anti thrombotics
    • Cardiac Therapies
    • Market analysis by drug class
    • Leading brands of Cardiac Therapies
    • Other cardiac therapies
    • Nitrites and nitrates
    • Leading-brand dynamics
    • Anti-arrhythmics
    • Sales forecasts to 2012 for Cardiac Therapies 2007-12
    • Total CVD market sales forecasts to 2012
  • Chapter 3 Pipeline analysis
    • Summary
    • Introduction
    • Key trends in cardiovascular R&D
    • Combination drugs
    • New class of drugs
    • New mechanism of action
    • New drug delivery formulations
    • The pipeline for cardiovascular disorders
    • Leading drugs in development
    • Profiles of key pipeline products
    • Phase II compounds
    • ARC 1779
    • KB 2115
    • Phase III compounds
    • Cleviprex (clevidipine)
    • Stedicor (azimilide)
    • BAY-597939 (rivaroxaban)
    • Drugs pending approval
    • Thelin (sitaxsentan)
    • Simcor (niacin and simvastatin)
    • Recently marketed drugs
    • Azor (amlodipine/olmesartan)
    • Tekturna/Rasilez (aliskiren)
    • Exforge (amlodipine/valsartan)
    • Ranexa (ranolazine)
  • Chapter 4 Competitive landscape
    • Summary
    • Company market shares
    • Pfizer
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Merck
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Novartis
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D compounds
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Sanofi Aventis
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • AstraZeneca
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Bristol-Myers Squibb
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Daiichi Sankyo
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Servier
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
    • Glaxo SmithKline
    • Overview
    • Sales focus by drug class
    • Marketed product portfolio
    • R&D pipeline analysis
    • Strategic and growth analysis
    • Drivers of growth
    • Resistors of growth
  • Chapter 5 Appendix
    • ATC codes used in analysis
    • Licensing status as per IMS Health
    • Original brand
    • Other brand
    • Licensed brand
    • Not-coded product
    • Unbranded/ generic product
    • Diagnosis profile analysis
  • Index
  • List of Figures
    • Figure 1.1: Relationship between Cardiovascular Risk Factors and Diseases
    • Figure 1.2: Typical treatment patterns in the treatment of hypertension
    • Figure 1.3: Typical treatment patterns in the treatment of dyslipidemia
    • Figure 1.4: Typical treatment patterns in the treatment of diabetes
    • Figure 1.5: Typical treatment patterns in the treatment of acute thrombotic events
    • Figure 2.6: Global cardiovascular market share by geography, 2007
    • Figure 2.7: Sales of types of cardiovascular brands, 2006-07
    • Figure 2.8: Competitive dynamics of the global CVD market by drug class, 2007
    • Figure 2.9: Forecast dynamics of the leading 10 cardiovascular brands, 2006-07
    • Figure 2.10: Competitive dynamics in the global anti-hypertensives market by drug class, 2006-07
    • Figure 2.11: Market movement for anti-hypertensive brands, 2006
    • Figure 2.12: Diagnosis profile of ACE inhibitor sales, 2006
    • Figure 2.13: Diagnosis profile of Beta Blockers, 2006
    • Figure 2.14: Diagnosis profile of Calcium channel blockers, 2006
    • Figure 2.15: Diagnosis profile of ARBs, 2006
    • Figure 2.16: Diagnosis profile of Anti-dyslipidemics, 2006
    • Figure 2.17: Competitive dynamics in the global anti-thrombotics market by class, 2006-07
    • Figure 2.18: Market movement for anti-thrombotic brands, 2006
    • Figure 2.19: Diagnosis profile of anti-platelets, 2006
    • Figure 2.20: Diagnosis profile of Heparins, 2006
    • Figure 2.21: Diagnosis profile of cardiac therapies, 2006
    • Figure 2.22: Competitive dynamics in the global cardiac therapies market by class, 2006-07
    • Figure 3.23: Prevailing R&D approaches for cardiovascular diseases, 2006
    • Figure 3.24: The CVD pipeline by indication and stage of development, 2006
    • Figure 3.25: Leading recently launched and late-stage cardiovascular products, 2007
    • Figure 4.26: Competitive dynamics of the leading players in the global cardiovascular market, 2007
    • Figure 4.27: Pfizer's franchise sales by drug class, 2006
    • Figure 4.28: Merck's franchise sales by drug class, 2006
    • Figure 4.29: Novartis' franchise sales by drug class, 2006
    • Figure 4.30: Sanofi Aventis' franchise sales by drug class, 2006
    • Figure 4.31: AstraZeneca's franchise sales by drug class, 2006
    • Figure 4.32: BMS' franchise sales by drug class, 2006
    • Figure 4.33: Daiichi's franchise sales by drug class, 2006
    • Figure 4.34: Servier's franchise sales by drug class, 2006
    • Figure 4.35: GSK's franchise sales by drug class, 2006
  • List of Tables
    • Table 1.1: Estimated prevalence of CVD across the seven major pharmaceutical markets, 2006
    • Table 1.2: Proposed revision definition of hypertension, 2005
    • Table 1.3: Estimated prevalence of hypertension in across seven major markets, 2006
    • Table 1.4: Forecast epidemiology of hypertension across the seven major markets, 2006-12
    • Table 1.5: Clinical guidelines for adult patients at borderline and high risk of cardiovascular disease by serum levels of lipids
    • Table 1.6: Estimated prevalence of dyslipidemia across seven major markets, 2006
    • Table 1.7: Forecast epidemiology of dyslipidemia across the seven major markets, 2006-12
    • Table 1.8: Various pharmacological therapies for the treatment and management of diabetes
    • Table 1.9: Estimated prevalence of diabetes in the seven major markets, 2006
    • Table 1.10: Forecast epidemiology of diabetes across the seven major markets, 2006-12
    • Table 1.11: Estimated prevalence of major cardiovascular diseases in the seven major markets, 2006
    • Table 1.12: Estimated incidence of ACS in the seven major markets, 2006
    • Table 1.13: Estimated incidence of VTE in the seven major markets, 2006
    • Table 1.14: Prevalence of stroke in the seven major markets, 2006
    • Table 1.15: Estimated incidence of cardiovascular procedures in the seven major markets, 2006
    • Table 2.16: Breakdown of the global CVD market by drug class, 2003-07
    • Table 2.17: Leading brands in the global cardiovascular market, 2006-07
    • Table 2.18: Breakdown of the global anti-hypertensive market by drug class, 2003-07
    • Table 2.19: Leading anti-hypertensive brands, 2006-07
    • Table 2.20: Leading ACE inhibitor brands, 2006-07
    • Table 2.21: Leading Beta blocker brands, 2006-07
    • Table 2.22: Leading diuretics brands, 2006-07
    • Table 2.23: Leading CCBs brands in the global CVD market, 2006-07
    • Table 2.24: Leading ARBs brands in the global CVD market, 2006-07
    • Table 2.25: Anti-hypertensives sales forecast for ARBs, Beta-blockers & CCBs, 2007-12
    • Table 2.26: Anti-hypertensives sales forecast for ACE inhibitors, Diuretics & Pipeline products, 2007-12
    • Table 2.27: Breakdown of the global anti-dyslipidemic market by drug class, 2003-07
    • Table 2.28: Leading anti-dyslipidemia products in the global CVD market, 2006-07
    • Table 2.29: Anti-dyslipidemics sales forecasts, 2007-12
    • Table 2.30: Breakdown of the global anti-thrombotics market by drug class, 2003-07
    • Table 2.31: Leading anti-thrombotics products in the global CVD market, 2006-07
    • Table 2.32: Leading anti-platelet brands in the global CVD market, 2006-07
    • Table 2.33: Leading heparin brands in the global CVD market, 2006-07
    • Table 2.34: Anti-thrombotics sales forecasts, 2007-12
    • Table 2.35: Breakdown of the global anti-thrombotics market by drug class, 2003-07
    • Table 2.36: Leading cardiac therapy products in the global CVD market, 2006-07
    • Table 2.37: Cardiac therapies' sales forecasts, 2007-12
    • Table 2.38: Cardiovacular market sales forecasts by drug class, 2006-12 ($m)
    • Table 4.39: Leading players in the global cardiovascular disorders market, 2006-07
    • Table 4.40: Pfizer's CVD product portfolio, 2005-06
    • Table 4.41: Pfizer's cardiovascular product pipeline, 2006
    • Table 4.42: Merck's CVD product portfolio, 2005-06
    • Table 4.43: Merck's cardiovascular R&D product pipeline, 2006
    • Table 4.44: Novartis' CVD product portfolio, 2005-06
    • Table 4.45: Novartis' cardiovascular R&D product pipeline, 2006
    • Table 4.46: Sanofi Aventis' CVD product portfolio, 2005-06
    • Table 4.47: Sanofi Aventis' cardiovascular R&D product pipeline, 2006
    • Table 4.48: AstraZeneca's CVD product portfolio, 2005-06
    • Table 4.49: AstraZeneca's cardiovascular R&D product pipeline, 2006
    • Table 4.50: BMS's CVD product portfolio, 2005-06
    • Table 4.51: BMS' cardiovascular R&D product pipeline, 2006
    • Table 4.52: Daiichi's CVD product portfolio, 2005-06
    • Table 4.53: Daichii's cardiovascular R&D product pipeline, 2006
    • Table 4.54: Servier's CVD product portfolio, 2005-06
    • Table 4.55: GSK's CVD product portfolio, 2005-06
    • Table 4.56: GSK's cardiovascular R&D product pipeline, 2006